The weekly litigation news digest is live. Subscribe now

IP Verse

ABBVIE INC. v. MACLEODS PHARMACEUTICAL LTD. - 3:25-cv-19038

ABBVIE INC. v. MACLEODS PHARMACEUTICAL LTD. (Case No. 3:25-cv-19038), filed on Dec 29, 2025 in the District Court, D. New Jersey involving patent infringement. This case involves patent infringement claims between the parties. Explore details about the litigants, key filings, and major docket updates.

Case Details

Case Number
3:25-cv-19038
Filing Date
Dec 29, 2025
Cause of Action
Patent Infringement
Status
-
Court
District Court, D. New Jersey
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

Parties Involved

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
MACLEODS PHARMACEUTICAL LTD. -
ABBVIE INC. -
ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED -

Patents Involved

This case involves 4 patents, each of which is central to the dispute. These patents may be subject to claims of infringement, challenges to their validity, or other issues concerning their scope and enforcement.

Application NumberPatent Number
-US12090148B2
-US12465598B2
-US12350259B2
-US12383545B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Dec 29, 2025NOTICE of Appearance by MARK M. MAKHAIL on behalf of ABBVIE INC., ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (MAKHAIL, MARK) (Entered: 12/29/2025)PACER Document
Dec 29, 2025Corporate Disclosure Statement by ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED identifying AbbVie Inc. as Corporate Parent.. (LINARES, JOSE) (Entered: 12/29/2025)PACER Document
Dec 29, 2025Corporate Disclosure Statement by ABBVIE INC.. (LINARES, JOSE) (Entered: 12/29/2025)PACER Document
Dec 29, 2025COMPLAINT against MACLEODS PHARMA USA, INC., MACLEODS PHARMACEUTICAL LTD. ( Filing and Admin fee $ 405 receipt number ANJDC-16947824), Related Case Selected, filed by ABBVIE INC., ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED. (Attachments: # 1 Exhibit A - U.S. Patent No. 12,090,148, # 2 Exhibit B - U.S. Patent No. 12,350,259, # 3 Exhibit C - U.S. Patent No. 12,383,545, # 4 Exhibit D - U.S. Patent No. 12,465,598, # 5 Civil Cover Sheet)(LINARES, JOSE) (Entered: 12/29/2025)PACER Document